Lisa Gallicchio, Ph.D.
- Ph.D. - Epidemiology, University of Maryland at Baltimore, Department of Epidemiology and Public Health
- M.S. - Epidemiology, University of Maryland at Baltimore, Department of Epidemiology and Public Health
- Cancer survivorship
- Cancer and aging
- Rare cancers
- Health disparities
- Epidemiologic methods
Dr. Lisa Gallicchio is a Program Director in the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). She is responsible for managing a research portfolio of grants focused on clinical, lifestyle, and genomic factors that affect outcomes among cancer survivors, including those factors that may contribute to observed disparities in health outcomes. Dr. Gallicchio, along with colleagues in DCCPS’s Behavioral Research Program, is leading the “Cancer and Accelerated Aging: Research for Healthier Survivors” initiative, which is focused on better understanding the effects that a cancer diagnosis and its treatment have on aging trajectories. Dr. Gallicchio also currently serves as co-chair of the Trans-NCI Cancer and Aging Coordinating Committee. Dr. Gallicchio’s other interests include better understanding the survivorship needs of individuals living with advanced cancer, post-diagnosis rare cancer outcomes and survivorship, the occurrence and effects of sleep disturbance and circadian rhythm disruption among cancer patients and survivors, and the application of epidemiologic methods to studying post-diagnosis cancer outcomes.
Prior to joining EGRP, Dr. Gallicchio was a Senior Epidemiologist in The Prevention and Research Center in the Weinberg Center for Women's Health & Medicine at Mercy Medical Center. During this time, she also served as an Adjunct Assistant Professor in the University of Maryland at Baltimore, Department of Epidemiology and Public Health and the Johns Hopkins University Bloomberg School of Public Health Department of Epidemiology. She was the Principal Investigator of a cohort study examining racial differences in the cardiovascular health effects of aromatase inhibitors, a hormonal therapy commonly used among breast cancer patients.
See listings of articles and other publications authored by Dr. Gallicchio in PubMed.